# Cagrilintide alone · PepVault guides

Source: https://pepvault.app/guides/renew-1-cagrilintide-results

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Cagrilintide alone: RENEW 1 phase 3 results and what to expect

Reviewed November 2026 20 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Cagrilintide alone in phase 3: what RENEW 1, 2 and 4 test, the 11.8% bar REDEFINE 1 set, how it compares with semaglutide, and when results are due.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 20
- **Questions:** 6
- **Compounds:** 3

## The short answer

RENEW 1 has not reported as of November 20, 2026. The phase 3 trial gives about 300 adults with obesity or overweight and no diabetes weekly cagrilintide 2.4 mg, Novo Nordisk's amylin drug, or placebo for 64 weeks. Novo expects results in the second half of 2027. The bar to meet: the 11.8% weight loss cagrilintide alone reached in REDEFINE 1 for people who stayed on treatment.

Every number checked at its primary source · Nov 20, 2026 · [20 sources](https://pepvault.app/guides/renew-1-cagrilintide-results#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** One phase 2 dose-finding trial in 906 people (Lancet 2021), a small phase 2 diabetes trial and a 302-person cagrilintide-alone arm of the phase 3 REDEFINE 1 trial (NEJM 2025, with Novo's sub-analysis), all funded by Novo Nordisk; RENEW 1, 2 and 4 have not reported, and cagrilintide is not approved anywhere.

## What does RENEW 1 test?

RENEW 1 is the first phase 3 trial built to test cagrilintide on its own, with no GLP-1 drug beside it. Adults with obesity (a BMI of 30 or more), or a BMI of 27 or more with a weight-related condition such as high blood pressure, and no diabetes, take a weekly shot of cagrilintide or a placebo (a dummy shot) for 64 weeks, with lifestyle counselling[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1). Two of every three get cagrilintide, and neither they nor the trial staff know who gets which[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1).

The primary endpoint, the one result the trial is built to test, is the percentage change in body weight from week 0 to week 64[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1). Novo Nordisk named the dose when it started the programme: cagrilintide 2.4 mg, in about 300 people[4](https://pepvault.app/guides/renew-1-cagrilintide-results#source-4). People who had ever taken an amylin drug, or any weight-loss medicine in the 180 days before screening, could not join[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1). Two sister trials run beside it.

| Trial | Who | Length | Primary endpoint | Size and status |
| --- | --- | --- | --- | --- |
| RENEW 1[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1) | Obesity or overweight, no diabetes | 64 weeks | Weight change at week 64 vs placebo | About 300 at 40 sites in 10 countries; enrolment closed |
| RENEW 2[2](https://pepvault.app/guides/renew-1-cagrilintide-results#source-2) | Obesity or overweight with type 2 diabetes | 64 weeks | Weight change at week 64 vs placebo | About 330 at 67 sites in 11 countries; enrolment closed |
| RENEW 4[3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3) | Obesity or overweight, no diabetes | 26 weeks | Weight change at week 26, two presentations vs placebo | About 285 at 36 sites in 6 countries; recruiting |

RENEW 2 is the diabetes trial, and its design has a twist: up to 30% of its participants may stay on a GLP-1 medicine they have taken at a stable dose for at least a year, so part of the trial tests amylin added on top[2](https://pepvault.app/guides/renew-1-cagrilintide-results#source-2). RENEW 4 is a device study. It compares two presentations of cagrilintide, one of them in a device that also carries a placebo matched to semaglutide, which reads like the two-chamber CagriSema pen; that reading is ours, not the registry's[3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault reminds you of a weekly shot on its day and logs each dose with its date, and its weight chart marks the day you started and every dose change, so you can set your own weeks beside a trial's.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What is amylin, and why test cagrilintide alone?

Amylin is a hormone the pancreas releases together with insulin after a meal. It slows how fast food leaves the stomach, holds back glucagon (the hormone that tells the liver to release sugar) and tells the brain you have eaten enough[15](https://pepvault.app/guides/renew-1-cagrilintide-results#source-15). One amylin drug is already approved: pramlintide (Symlin), for diabetes, injected before each major meal[15](https://pepvault.app/guides/renew-1-cagrilintide-results#source-15).

Cagrilintide is a long-acting amylin analogue, a built copy of the hormone made to last. In people its half-life, the time for half a dose to clear, measured 159 to 195 hours, about a week, in a trial that gave it with semaglutide, which is why it is a weekly shot[16](https://pepvault.app/guides/renew-1-cagrilintide-results#source-16).

Try it

How Cagrilintide builds up

An estimate from a half-life of about 7 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Cagrilintide in the library](https://pepvault.app/peptides/cagrilintide)

Novo already pairs it with semaglutide as CagriSema. The case for cagrilintide alone is choice: a different route to fullness for people who want or need something other than a GLP-1. Novo is testing that directly in a separate, smaller trial of people who stopped a GLP-1 drug because of stomach side effects, where the primary endpoint is how many are on cagrilintide's standard dose or higher at 26 weeks[17](https://pepvault.app/guides/renew-1-cagrilintide-results#source-17).

## What did the earlier cagrilintide trials show?

Three trials past phase 1 have reported weight results for cagrilintide alone, all funded by Novo. Two ways of counting appear below. The treatment-policy number counts everyone who started, including people who stopped the drug; the trial-product number estimates the result if everyone stayed on it, and runs a little higher.

| Trial | Who and how long | Weight change on cagrilintide | Placebo or comparator |
| --- | --- | --- | --- |
| Phase 2 dose-finding, 2021[9](https://pepvault.app/guides/renew-1-cagrilintide-results#source-9) [10](https://pepvault.app/guides/renew-1-cagrilintide-results#source-10) | 906 adults without diabetes (706 on cagrilintide), 26 weeks, doses 0.3 to 4.5 mg | −9.5% on 2.4 mg; −10.8% on 4.5 mg (registry's posted means) | −3.0% on placebo; −8.5% on liraglutide 3.0 mg (same) |
| Phase 2 in type 2 diabetes, 2023[11](https://pepvault.app/guides/renew-1-cagrilintide-results#source-11) | 30 adults on cagrilintide 2.4 mg, 32 weeks | −8.1% | −5.1% on semaglutide 2.4 mg; −15.6% on the pair |
| REDEFINE 1, phase 3, 2025[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6) [7](https://pepvault.app/guides/renew-1-cagrilintide-results#source-7) [8](https://pepvault.app/guides/renew-1-cagrilintide-results#source-8) | 302 adults without diabetes on cagrilintide 2.4 mg, 68 weeks | −11.8% (trial product); −11.5% (treatment policy) | Placebo −2.3% and −3.0%; semaglutide 2.4 mg alone −16.1% and −14.9% |

The REDEFINE 1 arm is the number RENEW 1 inherits. In that arm, 31.6% of people lost 15% or more of their weight if they stayed on treatment, against 4.7% on placebo[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6). Tolerability was the quiet headline: nausea made 1.0% stop cagrilintide for good, against 0.1% on placebo[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6), and at week 68, 82.5% were still on the full 2.4 mg dose, against 70.2% on semaglutide alone[7](https://pepvault.app/guides/renew-1-cagrilintide-results#source-7).

REDEFINE 1 was designed to test CagriSema against placebo; the cagrilintide-alone figures come from Novo's post hoc sub-analysis of a smaller arm, presented at EASD in September 2025[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6). RENEW 1 is the first trial to make cagrilintide alone its main question.

## With this guide

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 7 studies](https://pepvault.app/research#cagrilintide)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)
- [Cagrilintide vs Pramlintide](https://pepvault.app/peptides/compare/cagrilintide-vs-pramlintide)
- [Cagrilintide vs Eloralintide](https://pepvault.app/peptides/compare/cagrilintide-vs-eloralintide)
- [Cagrilintide vs Petrelintide](https://pepvault.app/peptides/compare/cagrilintide-vs-petrelintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

## Cagrilintide vs semaglutide: what would count as a good RENEW 1 result?

Set the bar before the number lands. Semaglutide 2.4 mg, the drug in Wegovy, lost 14.9% of body weight at 68 weeks in STEP 1, against 2.4% on placebo, counting everyone, and 50.5% of people lost 15% or more[12](https://pepvault.app/guides/renew-1-cagrilintide-results#source-12). No earlier trial puts cagrilintide alone above that. The question is whether it lands close, with fewer people put off by nausea.

- Weight: about 11% to 12% at 64 weeks would confirm REDEFINE 1, whose arm reached 11.5% counting everyone and 11.8% for people who stayed on[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6). RENEW 1 is four weeks shorter, so a number slightly under REDEFINE 1's would still be on track.
- The 15% mark: around 31% of people reaching 15% or more, as in REDEFINE 1[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6). STEP 1's semaglutide figure was 50.5%[12](https://pepvault.app/guides/renew-1-cagrilintide-results#source-12).
- Stopping for side effects: REDEFINE 1's 1.0% who stopped for nausea, against 0.1% on placebo, is the figure to hold[6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6). STEP 1 counted every stomach side effect, not nausea alone: 4.5% stopped semaglutide for one, against 0.8% on placebo[12](https://pepvault.app/guides/renew-1-cagrilintide-results#source-12). The two are different measures, so read the gap as a direction, not a size.
- Nausea itself: 31% had nausea on 2.4 mg in the phase 2 trial, against 18% on placebo[10](https://pepvault.app/guides/renew-1-cagrilintide-results#source-10); in STEP 1, 44% did on semaglutide, against 17%[13](https://pepvault.app/guides/renew-1-cagrilintide-results#source-13).
- RENEW 2: weight loss runs lower with type 2 diabetes. Semaglutide 2.4 mg lost 9.6% at 68 weeks in STEP 2, against 3.4% on placebo[14](https://pepvault.app/guides/renew-1-cagrilintide-results#source-14), and cagrilintide alone lost 8.1% in 32 weeks in the small diabetes trial[11](https://pepvault.app/guides/renew-1-cagrilintide-results#source-11).

A result in that range would make cagrilintide the first amylin-only weight drug with a full phase 3 case: less weight loss than semaglutide, gentler on the stomach. A result well above 12% would change the comparison with semaglutide outright.

**Commonly reported:** early fullness and smaller portions within the first weeks, nausea that is milder than on a GLP-1 and comes mostly after a step-up, and some redness or itching where the shot goes in, which the phase 2 trial also recorded[10](https://pepvault.app/guides/renew-1-cagrilintide-results#source-10).

## When will RENEW 1 results come out?

The registry's primary completion date for RENEW 1 is May 11, 2027, an estimate of when the last participant reaches the week-64 weigh-in, not a results date[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1). RENEW 2 follows on May 12 and RENEW 4 on May 18[2](https://pepvault.app/guides/renew-1-cagrilintide-results#source-2) [3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3). Novo said in its report of November 4, 2026 that it expects phase 3 results from RENEW 1 and 2 in the second half of 2027[5](https://pepvault.app/guides/renew-1-cagrilintide-results#source-5).

| Date | What could happen |
| --- | --- |
| May 11 to 18, 2027 | Primary completion of RENEW 1, 2 and 4, the registry's estimates[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1) [2](https://pepvault.app/guides/renew-1-cagrilintide-results#source-2) [3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3) |
| May 18 to 21, 2027 | European Congress on Obesity, Munich; its abstract deadline, January 15, falls before the data exist[18](https://pepvault.app/guides/renew-1-cagrilintide-results#source-18) |
| June 18 to 21, 2027 | American Diabetes Association Scientific Sessions, Washington, D.C.[19](https://pepvault.app/guides/renew-1-cagrilintide-results#source-19) |
| Second half of 2027 | Novo's stated window for RENEW 1 and 2 results[5](https://pepvault.app/guides/renew-1-cagrilintide-results#source-5) |
| September 21 to 24, 2027 | EASD Annual Meeting, Budapest; the REDEFINE 1 cagrilintide data were first shown at EASD in 2025[20](https://pepvault.app/guides/renew-1-cagrilintide-results#source-20) [6](https://pepvault.app/guides/renew-1-cagrilintide-results#source-6) |

The most likely first sight is a Novo company announcement with the topline numbers, as with REDEFINE 1[7](https://pepvault.app/guides/renew-1-cagrilintide-results#source-7), then a full presentation at a meeting. Novo also expects to start a high-dose cagrilintide phase 3 in the fourth quarter of 2026[5](https://pepvault.app/guides/renew-1-cagrilintide-results#source-5), so RENEW 1 may not be the last word on the dose.

<!--promo-->

PepVault reminds you of a weekly shot on its day and logs each dose with its date, and its weight chart marks the day you started and every dose change, so you can set your own weeks beside a trial's. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-renew-1-cagrilintide-results-inlin&mt=8)

<!--/promo-->

## Has RENEW 1 reported yet?

**Not reported as of November 20, 2026.** None of the three registry records has posted results[1](https://pepvault.app/guides/renew-1-cagrilintide-results#source-1) [2](https://pepvault.app/guides/renew-1-cagrilintide-results#source-2) [3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3), and Novo's latest report lists RENEW 1 and 2 as future milestones[5](https://pepvault.app/guides/renew-1-cagrilintide-results#source-5). When Novo releases the topline, this section will carry the average weight change at week 64 counting everyone and counting those who stayed on, the share reaching 10% and 15%, the rate of stopping for side effects, and RENEW 2's weight and blood sugar numbers beside them.

Cagrilintide is investigational: the registry describes it as a new medicine doctors cannot prescribe yet[3](https://pepvault.app/guides/renew-1-cagrilintide-results#source-3). For the drug itself, PepVault's cagrilintide page in the library covers its mechanism, half-life and side effects, the cagrilintide vs semaglutide comparison sets the two side by side, and the REDEFINE 1 and STEP 1 study pages hold the trials behind the bars above. The pair's own approval is the CagriSema FDA decision guide.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. ClinicalTrials.gov NCT07220642. RENEW 1: efficacy and safety of cagrilintide for weight management in participants with overweight or obesity (phase 3; sponsor Novo Nordisk A/S). Record updated August 6, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220642)
2. ClinicalTrials.gov NCT07220759. RENEW 2: efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes (phase 3; sponsor Novo Nordisk A/S). Record updated November 16, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220759)
3. ClinicalTrials.gov NCT07745504. RENEW 4: a placebo-controlled comparability study of two presentations of cagrilintide (phase 3; sponsor Novo Nordisk A/S). Record updated September 4, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745504)
4. Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2025 to 30 September 2025 (R&D update: RENEW programme initiated). November 5, 2025. [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm)
5. Novo Nordisk A/S, Form 6-K: Financial report for 1 January to 30 September 2026 (anticipated key R&D milestones). November 4, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm)
6. Novo Nordisk. Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme (company announcement, EASD 2025). September 16, 2025. [ml-eu.globenewswire.com](https://ml-eu.globenewswire.com/Resource/Download/358c0435-6f55-43c7-8ce5-6e5e9bddd890)
7. Novo Nordisk A/S, Form 6-K: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (company announcement No 99/2024). December 20, 2024. [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000117184324007023/f6k_122024.htm)
8. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. [PubMed 40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/)
9. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. [PubMed 34798060](https://pubmed.ncbi.nlm.nih.gov/34798060/)
10. ClinicalTrials.gov NCT03856047. Cagrilintide dose-finding phase 2 trial in people with overweight or obesity (sponsor Novo Nordisk A/S): posted results, July 18, 2023. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03856047)
11. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10403):720-730. [PubMed 37364590](https://pubmed.ncbi.nlm.nih.gov/37364590/)
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. [PubMed 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
13. ClinicalTrials.gov NCT03548935. STEP 1, semaglutide 2.4 mg in adults with overweight or obesity (sponsor Novo Nordisk A/S): posted results, adverse events. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03548935)
14. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed 33667417](https://pubmed.ncbi.nlm.nih.gov/33667417/)
15. SYMLINPEN (pramlintide acetate) injection prescribing information, sections 1, 2 and 12.1. AstraZeneca. DailyMed, version 18, August 2024. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff)
16. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg: a phase 1b trial. Lancet. 2021;397(10286):1736-1748. [PubMed 33894838](https://pubmed.ncbi.nlm.nih.gov/33894838/)
17. ClinicalTrials.gov NCT07607587. Tolerability of cagrilintide in people with obesity who stopped GLP-1 therapies because of gastrointestinal side effects (sponsor Novo Nordisk A/S). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607587)
18. ECO2027: the 34th European Congress on Obesity, Munich, 18-21 May 2027; abstract deadline 15 January 2027 (congress site). [eco2027.org](https://eco2027.org/)
19. American Diabetes Association. 2027 Scientific Sessions, Washington, D.C., June 18-21, 2027 (save the date). [professional.diabetes.org](https://professional.diabetes.org/scientific-sessions)
20. EASD. 63rd EASD Annual Meeting, Budapest, 21-24 September 2027. [easd.org](https://www.easd.org/annual-meeting/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)

Wegovy HD 7.2 mg against 2.4 mg in the STEP UP trials: the extra weight lost, who reached 20% and 25%, the side effects side by side, and who the label allows.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Cagrilintide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrilintide)
- [CagriSema Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrisema)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)

  CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 7 studies](https://pepvault.app/research#cagrilintide)
- [All 4 studies](https://pepvault.app/research#cagrisema)

### Compared with

- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)
- [Cagrilintide vs Pramlintide](https://pepvault.app/peptides/compare/cagrilintide-vs-pramlintide)
- [Cagrilintide vs Eloralintide](https://pepvault.app/peptides/compare/cagrilintide-vs-eloralintide)
- [Cagrilintide vs Petrelintide](https://pepvault.app/peptides/compare/cagrilintide-vs-petrelintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
